A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a ...

The FDA has extended its approval of UCB’s BIMZELX to three new indications, extending the use of the drug to a total of four ...

David Carbone, Director of the James Thoracic Oncology Center and Professor of Internal Medicine at The Ohio State University ...

MinervaX and Wacker Biotech announced yesterday that they have entered into a manufacturing agreement for MinervaX’s ...

UCB and Biogen revealed that their Phase 3 study testing dapirolizumab pegol in people with systemic lupus erythematosus met ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

The series B fundraising will support the clinical development of next-generation multivalent vaccines against respiratory ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

Although vaccines already exist to prevent mpox, high prices and the risk of side effects make it difficult to roll them out ...

The FDA has granted Orphan Drug and Rare Pediatric Disease Designations to Somite’s cell replacement therapy for the ...

The new company focuses on producing components needed to manufacture RNA-based therapies for which there is increasing ...